Secretory phospholipase A2 mediates human esophageal adenocarcinoma cell growth and proliferation via ERK 1/2 pathway

Anticancer Research

Volumn 33, Issue 4, 2013, Pages 1337-1342

  Sadaria, Miral R ^a   Yu, Jessica A ^a   Meng, Xianzhong ^a   Fullerton, David A ^a   Reece, T Brett ^a   Weyant, Michael J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

ERK 1 2; Esophageal adenocarcinoma; Growth; Proliferation; Secretory phospholipase A2

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; MITOGEN ACTIVATED PROTEIN KINASE 3; SECRETORY PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA; ENZYME INHIBITOR; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; ADENOCARCINOMA; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; ESOPHAGUS TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME INHIBITORS; ESOPHAGEAL NEOPLASMS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASES A2, SECRETORY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

MLCS; MLOWN;

EID: 84876750319     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kubo A and Corley DA: Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 95: 2096-2102, 2002. (Pubitemid 35253370)
2. Brown LM, Devesa SS and Chow WH: Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 100: 1184-1187, 2008.
3. Jankowski JA, Perry I and Harrison RF: Gastro-oesophageal cancer: Death at the junction. BMJ 321: 463-464, 2000. (Pubitemid 30623596)
4. di Pietro M, Peters CJ and Fitzgerald RC: Clinical puzzle: Barrett's oesophagus. Dis Model Mech 1: 26-31, 2008.
5. Jankowski JA, Harrison RF, Perry I, Balkwill F and Tselepis C: Barrett's metaplasia. Lancet 356: 2079-2085, 2000. (Pubitemid 32009828)
6. Ogunwobi OO and Beales IL: Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 103: 825-837, 2008. (Pubitemid 351501115)
7. Balmanno K and Cook SJ: Tumour cell survival signaling by the ERK 1/2 pathway. Cell Death Diff 16: 368-377, 2009.
8. Calvo E, Bolós V and Grande E: Multiple roles and therapeutic implications of Akt signaling in cancer. Onco Targets and Ther 2: 135-150, 2009.
9. 2-IIA (Pla2g2a) in cancer of the small and large intestine. Front Biosci 13: 4144-4174, 2008. (Pubitemid 351611597)
10. 2 as multivalent mediators of inflammatory and allergic disorders. Int Arch Allergy Immunol 131: 153-163, 2003. (Pubitemid 36921053)
11. 2 expression and activity in murine esophagus. Dis Esophagus 23: 430-436, 2010.
12. 2 is required to produce histologic changes associated with gastroduodenal reflux in a murine model. J Thorac Cardiovasc Surg 135: 1220-1227, 2008. (Pubitemid 351787654)
13. Mauchley D, Meng X, Johnson T, Fullerton DA and Weyant MJ: Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A2. J Thorac Cardiovasc Surg 139: 591-599, 2010.
14. 2 inhibition attenuates intercellular adhesion molecule-1 expression in human esophageal adenocarcinoma cells. Ann Thor Surg 91: 1539-1545, 2011.
15. Martín R, Hernández M, Ibeas E, Fuentes L, Salicio V, Arnés M and Nieto ML: Secreted phospholipase A2-IIA modulates key regulators of proliferation on astrocytoma cells. J Neurochem 111: 988-999, 2009.
16. Sadaria MR, Reppert AE, Yu JA, Meng X, Fullerton DA, Reece TB and Weyant MJ: Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg 142: 1152-1160, 2010.
17. Santarpia L, Lippman SM and El-Naggar AK: Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16: 103-119, 2012.
18. 1- to S-phase transition. Oncogene 26: 3227-3239, 2007. (Pubitemid 46763017)
19. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007. (Pubitemid 47125967)
20. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G and Cervello M: Emerging MEK inhibitors. Expert Opin Emerg Drugs 15: 203-223, 2010.